Latest News

Prime minister Scott Morrison has set out his expectation of the public service but said it needs to look beyond the "highly organised and well-resourced interests in our democracy" when it comes to stakeholder engagement.

Sanofi has partnered with the Australian Diabetes Educators Association to launch a new support for people with diabetes prescribed the company's insulins.

AbbVie's Kirsten O'Doherty, Pfizer's Melissa McGregor and Kathy Connell of Johnson & Johnson Innovation, discuss the group's creation, its progress and achievements, their personal reflections and experiences.

The podcasts will feature issues relevant to the biopharmaceutical sector - and we want to hear from you about ideas for topics and episodes.

Sanofi marked National Science Week by hosting more than 20 students from Sydney’s Chester Hill High School in its offices for a two-day 'Work Inspiration' program with The Smith Family.

The industry backs greater transparency in public summary documents but has warned the current proposed changes risk undermining PBAC decision-making - BioPharmaDispatch explores these concerns and the ramifications.

The emergence of regenerative medicine has a number of implications for the health system - some known, some unknown.

Ten years ago, a meeting of research-based companies would have involved a group of organisations with shared interests based on similar product portfolios - this has become less and less the case and it will become even less likely in the years ahead.

Clinicians and patients have welcomed another TGA approval of Roche's PD-L1 inhibitor immunotherapy TECENTRIQ (atezolizumab) for a new indication. 

Patient Voice Aotearoa says another nine petitions have been launched asking that New Zealand's PHARMAC fund medicines for diabetes, cystic fibrosis, bowel cancer, head and neck cancer, brain cancer, epilepsy/mental health, phenylketonuria, Fabry disease and Lynch syndrome.

A new report has highlighted the shift from 'one-size-fits-all treatments' to 'personalised interventions' based on individual patient biology and genetics as a major trend in Australia's health system over the next two decades.

Sydney-based company Noxopharm is developing a new approach to cancer treatment that is designed to convert 'cold' tumours to 'hot'' so they can be recognised by the immune system.